{
    "ticker": "SYNX",
    "name": "Synlogic, Inc.",
    "description": "Synlogic, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for genetic diseases and metabolic disorders. Founded in 2014 and headquartered in Cambridge, Massachusetts, Synlogic leverages its proprietary Synthetic Biotic platform to engineer living medicines that are designed to treat diseases by restoring missing or dysfunctional biological pathways. The company's lead product candidates, including SYNB1618 for the treatment of phenylketonuria (PKU) and SYNB1934 for the treatment of urea cycle disorders, are developed to provide patients with effective, safe, and convenient treatment options. Synlogic's approach combines synthetic biology and metabolic engineering to create beneficial bacteria that can be administered orally to produce therapeutic effects in the body. This innovative technology positions Synlogic at the forefront of a new class of therapies that have the potential to transform the treatment landscape for a variety of diseases. With a strong commitment to scientific excellence and patient-centricity, Synlogic aims to unlock the potential of living medicines to improve the health and quality of life for patients around the world.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.synlogic.com",
    "ceo": "David A. L. F. F. C. L. Ko",
    "social_media": {
        "twitter": "https://twitter.com/Synlogic",
        "linkedin": "https://www.linkedin.com/company/synlogic/"
    },
    "investor_relations": "https://investors.synlogic.com",
    "key_executives": [
        {
            "name": "David A. L. F. F. C. L. Ko",
            "position": "CEO"
        },
        {
            "name": "Paul E. J. M. G. S. A. T. R. H. L. C. O. G. R. S. O.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "SYNB1618",
                "SYNB1934"
            ]
        }
    ],
    "seo": {
        "meta_title": "Synlogic, Inc. | Living Medicines for Genetic Diseases",
        "meta_description": "Explore Synlogic, Inc., a leader in synthetic biology focused on developing innovative therapies for genetic and metabolic disorders. Learn more about their transformative approach.",
        "keywords": [
            "Synlogic",
            "Biotechnology",
            "Living Medicines",
            "Genetic Diseases",
            "Metabolic Disorders",
            "SYNB1618",
            "SYNB1934"
        ]
    },
    "faq": [
        {
            "question": "What is Synlogic known for?",
            "answer": "Synlogic is known for developing living medicines using synthetic biology to treat genetic diseases and metabolic disorders."
        },
        {
            "question": "Who is the CEO of Synlogic?",
            "answer": "David A. L. F. F. C. L. Ko is the CEO of Synlogic, Inc."
        },
        {
            "question": "Where is Synlogic headquartered?",
            "answer": "Synlogic is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Synlogic's main products?",
            "answer": "Synlogic's main products include SYNB1618 and SYNB1934, targeting genetic diseases such as PKU and urea cycle disorders."
        },
        {
            "question": "When was Synlogic founded?",
            "answer": "Synlogic was founded in 2014."
        }
    ],
    "competitors": [
        "VRTX",
        "BLRX",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}